{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:12:27Z","timestamp":1793873547823,"version":"4.6.1"},"reference-count":26,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14712598.2026.2667333","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:47:53Z","timestamp":1777474073000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer"],"prefix":"10.1080","volume":"26","author":[{"given":"Irfan","family":"Cicin","sequence":"first","affiliation":[{"name":"Istinye University, Faculty of Medicine, Topkapi Liv Hospital","place":["\u0130stanbul, Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00444-8"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02243-6"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00566-0"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S231257"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01144-9"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03701-9"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.06.008"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.07.021"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.015"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.2160"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.4274\/ThoracResPract.2025.2025-6-4"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1568"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764"},{"key":"e_1_3_6_19_1","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for non-small cell lung cancer with high c-Met protein overexpression Silver Spring. (MD): FDA; 2025 [cited 2025 Jun 15]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.7697"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0765"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3815"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00739"},{"issue":"28","key":"e_1_3_6_24_1","first-page":"3287","article-title":"Telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing EGFR-Mutated advanced non-small cell lung cancer","volume":"42","author":"Camidge DR","year":"2024","unstructured":"Camidge DR, Bar J, Goldman JW, et al. Telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing EGFR-Mutated advanced non-small cell lung cancer. J Clin Oncol. 2024;42(28):3287\u20133296.","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(25)03492-1"},{"key":"e_1_3_6_26_1","unstructured":"ClinicalTrials.gov. A study of telisotuzumab vedotin (ABBV-399) versus docetaxel in adults with Previously treated c-Met+ non-squamous non-small cell lung cancer (TeliMET NSCLC-01). Bethesda (MD): National Library of Medicine; 2021 Available from: https:\/\/clinicaltrials.gov\/study\/NCT04928846"},{"key":"e_1_3_6_27_1","unstructured":"ClinicalTrials.gov. A study of telisotuzumab vedotin (ABBV-399) in combination with osimertinib in adults with non-small cell lung cancer. Bethesda (MD): National Library of Medicine; 2022 [cited 2025 Jun 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06093503"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.001"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2667333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:37:59Z","timestamp":1779950279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2667333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14712598.2026.2667333"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2667333","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}